SOURCE: Rosetta Genomics, Ltd.

September 23, 2013 09:02 ET

Rosetta Genomics' Cancer Origin Test Highlighted on The Dr. Steve Show

Patient Story Underscores the Need for Accurate Diagnosis of Tumor Origin as the First Ever Cancer of Unknown Primary Awareness Week Launches

PRINCETON, NJ and REHOVOT, ISRAEL--(Marketwired - Sep 23, 2013) - Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the Rosetta Cancer Origin Test™ will be featured in an upcoming episode on The Dr. Steve Show, a nationally syndicated 30-minute health, well-being and lifestyle program. The segment is expected to air the first weekend in October 2013 in the following markets:

New York 
Sun 6:30PM

Sat 12:30PM

Sun 9:00AM

Separately, the Company congratulates the Cancer of Unknown Primary (CUP) Foundation's launch of the first annual "CUP Awareness Week" taking place from September 23-29, 2013, which is expected to raise awareness for this little known diagnostic dilemma. "We applaud the efforts of the CUP Foundation in providing valuable information and support to CUP patients and their families," said E. Robert Wassman, MD, FAAP, FACMG, Rosetta Genomics' Chief Medical Officer. "The reality is that a diagnosis of CUP is not a diagnosis at all, and can lead to increased patient anxiety and frustration with their care, as illustrated in our patient story highlighted on the Dr. Steve Show. With new advances in molecular diagnostics such as the Cancer Origin Test, an unknown or uncertain diagnosis is unacceptable." 

The episode features "Bernard's Story," a chronicle of this patient's compelling journey commencing with a Cancer of Unknown Primary diagnosis and the frustrations and difficulties associated with not knowing his cancer's tissue of origin. The story then moves forward with the cancer's origin being identified through the use of Rosetta Genomics Cancer Origin Test, and the patient's subsequent clinical and emotional benefits associated with having this critical knowledge.

"This feature brings to life the critical need to know the tumor of origin in order to guide treatment decisions and patient outcomes," stated Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. "Developments in targeted cancer therapies are driving the need for more accurate classification of tumor types, which help to guide treatment decisions. Our microRNA technologies, with their high reproducibility, robustness, and accuracy are well suited to provide valuable clinical information to predict and diagnose cancer, and therefore, help to optimize treatment as illustrated in this patient's story."

About the Dr. Steve Show
Dr. Steve is a 30-minute health, wellness and lifestyle program. The multi-topic show is hosted by Dr. Steve Salvatore, a board certified Emergency Medicine physician who has served as the health expert on PIX11 Morning News since 2005. Dr. Steve features a mix of wellness topics including fitness and nutrition experts, kitchen nutrition makeovers, gadget and product reviews, children's health and topical parenting issues. Dr. Steve also features everyday heroes, profiles of ordinary people with extraordinary stories.

About Rosetta Cancer Testing Services Rosetta Cancer Tests are a series of microRNA-based diagnostic testing services offered by Rosetta Genomics. The Rosetta Cancer Origin Test™ can accurately identify the primary tumor type in primary and metastatic cancer including cancer of unknown or uncertain primary (CUP). The Rosetta Mesothelioma Test™ diagnoses mesothelioma, a cancer connected to asbestos exposure. The Rosetta Lung Cancer Test™ accurately identifies the four main subtypes of lung cancer using small amounts of tumor cells. The Rosetta Kidney Cancer Test™ accurately classifies the four most common kidney tumors: clear cell renal cell carcinoma (RCC), papillary RCC, chromophobe RCC and the benign oncocytoma. Rosetta's assays are designed to provide objective diagnostic data; it is the treating physician's responsibility to diagnose and administer the appropriate treatment. In the U.S. alone, Rosetta Genomics estimates that 200,000 patients a year may benefit from the Cancer Origin Test, 60,000 from the Mesothelioma Test, 65,000 from the Kidney Cancer Test and 226,000 patients from the Lung Cancer Test. The Company's assays are offered directly by Rosetta Genomics in the U.S., and through distributors around the world. For more information, please visit Parties interested in ordering the test can contact Rosetta Genomics at (215) 382-9000 ext. 309.

About Rosetta Genomics
Rosetta develops and commercializes a full range of microRNA-based molecular diagnostics. Founded in 2000, Rosetta's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Rosetta's cancer testing services are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab. Frost & Sullivan recognized Rosetta Genomics with the 2012 North American Next Generation Diagnostics Entrepreneurial Company of the Year Award.

Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, Rosetta's Cancer of Origin Test, the Cancer Origin Test improving the ability of physicians to accurately diagnose CUP, the Cancer Origin Test's ability to help physicians to optimize treatment, Rosetta's development or commercialization of molecular diagnostics, the market acceptance of Rosetta's cancer testing services, particularly the Cancer Origin Test, the featuring of Rosetta Genomics and/or the Cancer Origin Test in the Dr. Steve Show, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2012 as filed with the SEC. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Contact Information